Relationship between RAS Association Domain Family Protein 1A Promoter Methylation and the Clinicopathological Characteristics in Patients with Ovarian Cancer: A Systematic Meta-Analysis

2017 ◽  
Vol 83 (4) ◽  
pp. 349-357 ◽  
Author(s):  
Hong Wang ◽  
Manhua Cui ◽  
Shuangli Zhang ◽  
Jie He ◽  
Li Song ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Promoter Methylation ◽  
Meta Analysis ◽  
Clinicopathological Characteristics ◽  
Domain Family ◽  
Family Protein

Role of RASSF1A Promoter Methylation in the Pathogenesis of Ovarian Cancer: A Meta-Analysis

2014 ◽  
Vol 18 (6) ◽  
pp. 394-402 ◽  
Author(s):  
Jin-Ge Si ◽  
Yuan-Yuan Su ◽  
Yan-Hua Han ◽  
Ru-Hong Chen
Keyword(s):  
Ovarian Cancer ◽  
Promoter Methylation ◽  
Meta Analysis

scholarly journals Association between P16INK4a Promoter Methylation and Ovarian Cancer: A Meta-Analysis of 12 Published Studies

PLoS ONE ◽  
2016 ◽  
Vol 11 (9) ◽  
pp. e0163257 ◽  
Author(s):  
Xiyue Xiao ◽  
Fucheng Cai ◽  
Xun Niu ◽  
Hao Shi ◽  
Yi Zhong
Keyword(s):  
Ovarian Cancer ◽  
Promoter Methylation ◽  
Meta Analysis

scholarly journals Identification of RASSF1A Promoter Hypermethylation as a Biomarker for Hepatocellular Carcinoma

2020 ◽  
Author(s):  
Gang Xu ◽  
Xiaoxiang Zhou ◽  
Jiali Xing ◽  
Yao Xiao ◽  
Bao Jin ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Promoter Methylation ◽  
Meta Analysis ◽  
Promoter Hypermethylation ◽  
Analysis Data ◽  
Clinicopathological Characteristics ◽  
The Cancer Genome Atlas ◽  
Large Tumor ◽  
Kaplan Meier ◽  
Cancer Genome Atlas

Abstract Background: RAS association domain family protein 1A (RASSF1A) promoter hypermethylation is suggested to be linked to hepatocellular carcinoma (HCC), but the results remained controversial.Methods: We evaluated how RASSF1A promoter hypermethylation affects HCC risk and its clinicopathological characteristics through meta-analysis. Data on DNA methylation in HCC and relevant clinical data were also collected based on The Cancer Genome Atlas (TCGA) database to investigate the prognostic role of RASSF1A promoter hypermethylation in HCC.Results: Forty-four articles involving 4,777 individuals were enrolled in the pooled analyses. The RASSF1A promoter methylation rate was notably higher in the HCC cases than the non-tumor cases and healthy individuals, and was significantly related to hepatitis B virus (HBV) infection-positivity and large tumor size. Kaplan–Meier survival analysis revealed that HCC cases with RASSF1A promoter hypermethylation had worse outcomes. Receiver operating characteristic curves confirmed that RASSF1A promoter methylation may be a marker of HCC-related prognoses.Conclusions: RASSF1A promoter hypermethylation is a promising biomarker for the diagnosis of HCC from tissue and peripheral blood, and is an emerging therapeutic target against HCC.

scholarly journals BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis

2020 ◽  
Vol 112 (12) ◽  
pp. 1190-1203 ◽  
Author(s):  
Roshni D Kalachand ◽  
Britta Stordal ◽  
Stephen Madden ◽  
Benjamin Chandler ◽  
Julie Cunningham ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Statistical Tests ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Clinicopathological Characteristics ◽  
Mixed Effects ◽  
Mixed Effects Modeling ◽  
Brca1 Promoter Methylation ◽  
Individual Participant ◽  
Survival Differences

Abstract Background BRCA1 methylation has been associated with homologous recombination deficiency, a biomarker of platinum sensitivity. Studies evaluating BRCA1-methylated tubal and ovarian cancer (OC) do not consistently support improved survival following platinum chemotherapy. We examine the characteristics of BRCA1-methylated OC in a meta-analysis of individual participant data. Methods Data of 2636 participants across 15 studies were analyzed. BRCA1-methylated tumors were defined according to their original study. Associations between BRCA1 methylation and clinicopathological characteristics were evaluated. The effects of methylation on overall survival (OS) and progression-free survival (PFS) were examined using mixed-effects models. All statistical tests were 2-sided. Results 430 (16.3%) tumors were BRCA1-methylated. BRCA1 methylation was associated with younger age and advanced-stage, high-grade serous OC. There were no survival differences between BRCA1-methylated and non–BRCA1-methylated OC (median PFS = 20.0 vs 18.5 months, hazard ratio [HR] = 1.01, 95% CI = 0.87 to 1.16; P = .98; median OS = 46.6 vs 48.0 months, HR = 1.02, 95% CI = 0.87 to 1.18; P = .96). Where BRCA1/2 mutations were evaluated (n = 1248), BRCA1 methylation displayed no survival advantage over BRCA1/2-intact (BRCA1/2 wild-type non–BRCA1-methylated) OC. Studies used different methods to define BRCA1 methylation. Where BRCA1 methylation was determined using methylation-specific polymerase chain reaction and gel electrophoresis (n = 834), it was associated with improved survival (PFS: HR = 0.80, 95% CI = 0.66 to 0.97; P = .02; OS: HR = 0.80, 95% CI = 0.63 to 1.00; P = .05) on mixed-effects modeling. Conclusion BRCA1-methylated OC displays similar clinicopathological features to BRCA1-mutated OC but is not associated with survival. Heterogeneity within BRCA1 methylation assays influences associations. Refining these assays may better identify cases with silenced BRCA1 function and improved patient outcomes.

Meta-analysis demonstrates no association between p16 ink4a promoter methylation and epithelial ovarian cancer

2016 ◽  
Vol 295 (3) ◽  
pp. 697-704 ◽  
Author(s):  
Yi Jiang ◽  
Fangrong Yan ◽  
Li Liang ◽  
Yicong Wan ◽  
Jinsong Liu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Promoter Methylation ◽  
Meta Analysis ◽  
P16 Ink4a
Sign in / Sign up

Export Citation Format

Share Document